Johnson & Johnson (JNJ) Short-Term Debt issuances (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Short-Term Debt issuances came in at $707.0 million in Q2 2026, up 25.13% year-over-year from $565.0 million in Q2 2025, and down 94.32% quarter-over-quarter from $12.4 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Short-Term Debt issuances (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Short-Term Debt issuances across 18 years of filings, most recently posting $707.0 million for Q2 2026.
- In Q2 2026, Short-Term Debt issuances rose 25.13% year-over-year to $707.0 million; the TTM figure through Jun 2026 stood at $18.4 billion (up 72.61% YoY), while the FY2025 annual figure was $14.6 billion, down 4.52% from the prior year.
- Short-Term Debt issuances came in at $707.0 million for Q2 2026 at Johnson & Johnson, down from $12.4 billion in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $14.9 billion in Q1 2023 to a low of -$2.0 billion in Q3 2024.
- Average Short-Term Debt issuances over 5 years is $5.2 billion, with a median of $3.6 billion recorded in 2024.
- Year-over-year, Short-Term Debt issuances soared 535.58% in 2022 and plunged 124.79% in 2024.
- Over 5 years, Short-Term Debt issuances stood at $3.0 billion in 2022, then tumbled by 56.01% to $1.3 billion in 2023, then soared by 147.97% to $3.3 billion in 2024, then gained by 18.83% to $3.9 billion in 2025, then sank by 81.93% to $707.0 million in 2026.
- Per Business Quant data, the three most recent Short-Term Debt issuances figures were $707.0 million in Q2 2026, $12.4 billion in Q1 2026, and $3.9 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 707.00 Mn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 4.94 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 208.00 Mn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 64.00 Mn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | - |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 707.00 Mn |
| Mar 29, 2026 | 12.44 Bn |
| Dec 28, 2025 | 3.91 Bn |
| Sep 28, 2025 | 1.32 Bn |
| Jun 29, 2025 | 565.00 Mn |
| Mar 30, 2025 | 8.78 Bn |
| Dec 29, 2024 | 3.29 Bn |
| Sep 29, 2024 | -1.99 Bn |
| Jun 30, 2024 | 8.71 Bn |
| Mar 31, 2024 | 5.26 Bn |
| Dec 31, 2023 | 1.33 Bn |
| Oct 1, 2023 | 8.03 Bn |
| Jul 2, 2023 | 2.52 Bn |
| Apr 2, 2023 | 11.09 Bn |
| Jan 1, 2023 | 14.85 Bn |
| Apr 3, 2022 | 3.02 Bn |
| Oct 3, 2021 | 594.00 Mn |
| Jul 4, 2021 | 214.00 Mn |
| Apr 4, 2021 | 475.00 Mn |
| Jan 3, 2021 | 56.00 Mn |